Connecticut Patent of the Month – July 2023

Lumeda Inc., a clinical-stage medical technology company, has patented their optical light delivery technology. This device is designed to enhance therapy light transmission and produce a uniform irradiance pattern for photodynamic therapy (PDT) procedures in lung cancer treatment.

The optical light delivery device is designed with a series of source emitting devices which deliver therapy light with precision scattering and distribution. To ensure optimal light scattering and distribution, the device utilizes a flexible matrix made of a material with a high scattering coefficient (greater than 5 cm^-1). This matrix encapsulates and spatially fixes the source emitting devices, ensuring their parallel alignment.

To detect the light emitted by the source emitting devices, the optical light delivery device includes detector fibers, which are also encapsulated and spatially fixed within the flexible matrix. The detector fiber is positioned in close proximity to the source emitting devices and is coupled to a detector. This configuration enables accurate and efficient light detection.

In addition to the source emitting devices and detector fibers, the system includes an integrated optical applicator. This applicator incorporates the flexible matrix, providing superior light scattering properties. The source emitting devices within the applicator are spatially fixed at a predetermined standoff position from the application side. This arrangement ensures precise and controlled light delivery to the target area.

The integrated optical applicator aims to achieve a highly uniform irradiance pattern, which is crucial for effective therapy. It also offers the flexibility to produce a predetermined fluence at the application side, allowing customization according to specific treatment requirements.

By combining the system with a therapy light source and a photosensitizing drug, medical professionals can perform PDT procedures with enhanced precision and effectiveness. The system is engineered and designed based on novel PDT light delivery technology, allowing for a fully automated system which makes PDT procedures faster, easier to administer, and leads to repeatable and reliable therapeutic results.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts